Comment on FDA's Breakthrough Therapy Designation of Intranasal Esketamine for the Treatment of Major Depressive Disorder with Imminent Risk of Suicide
about
Comment on FDA's Breakthrough Therapy Designation of Intranasal Esketamine for the Treatment of Major Depressive Disorder with Imminent Risk of Suicide
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 2016
@uk
name
Comment on FDA's Breakthrough ...... with Imminent Risk of Suicide
@en
Comment on FDA's Breakthrough ...... with Imminent Risk of Suicide
@nl
type
label
Comment on FDA's Breakthrough ...... with Imminent Risk of Suicide
@en
Comment on FDA's Breakthrough ...... with Imminent Risk of Suicide
@nl
prefLabel
Comment on FDA's Breakthrough ...... with Imminent Risk of Suicide
@en
Comment on FDA's Breakthrough ...... with Imminent Risk of Suicide
@nl
P2093
P2860
P1476
Comment on FDA's Breakthrough ...... with Imminent Risk of Suicide
@en
P2093
Glen B. Baker
Reji Thomas
Serdar M. Dursun
P2860
P304
P356
10.5455/BCP.20161027122045
P50
P577
2016-12-01T00:00:00Z